Templates by BIGtheme NET
healthcare-cloud

HC Stocks Broker Alerts- Biocept Inc (BIOC), CytRx Corporation (CYTR)

Shares of Biocept Inc (NASDAQ:BIOC) ended Tuesday session in red amid volatile trading. The shares closed down -0.05 points or -3.52% at $1.37 with 68,126 shares getting traded. Post opening the session at $1.45, the shares hit an intraday low of $1.31 and an intraday high of $1.46 and the price vacillated in this range throughout the day. The company has a market cap of $11.19 million and the numbers of outstanding shares have been calculated to be 8.40 million shares.

Biocept Inc (BIOC) announced a research collaboration with Shilpa Gupta, Ph.D., Assistant Professor in the Hematology Oncology and Transplantation Division of the University of Minnesota to observe the utility of Biocept’s patented Target Selector™ liquid biopsy technology platform using circulating tumor cells (CTCs) to detect the expression of PD-L1 and androgen receptor (AR) in patients diagnosed with bladder and prostate cancers.  The study will be conducted at the University of Minnesota Masonic Cancer Center. PD-L1 is expressed in multiple cancer types and its status is required to qualify patients for certain immuno-oncology therapeutics. AR expression is prevalent in patients with advanced prostate cancer.

Shares of CytRx Corporation (NASDAQ:CYTR) ended Tuesday session in red amid volatile trading. The shares closed down -0.020 points or -3.65% at $0.523 with 822,180 shares getting traded. Post opening the session at $0.54, the shares hit an intraday low of $0.52 and an intraday high of $0.55 and the price vacillated in this range throughout the day. The company has a market cap of $51.02 million and the numbers of outstanding shares have been calculated to be 96.94 million shares.

CytRx Corporation (CYTR) operates as a biopharmaceutical research and development company specializing in oncology. The companys product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi’s sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors.

 

 

 

About James Smith

James Smith is one of the best author of health care. His articles have appeared in a number of health care sites before and now he is writing on health care for us on regular basis.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

ăn dặm kiểu NhậtResponsive WordPress Themenhà cấp 4 nông thônthời trang trẻ emgiày cao gótshop giày nữdownload wordpress pluginsmẫu biệt thự đẹpepichouseáo sơ mi nữhouse beautiful